Top 10 Companies in the (R)-N-BOC-4-Bromophenylalanine (CAS 79561-82-3) Market (2026): Market Leaders Powering Global Peptide Synthesis

MARKET INSIGHTS

Global (R)-N-BOC-4-Bromophenylalanine (CAS 79561-82-3) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(R)-N-BOC-4-Bromophenylalanine (CAS 79561-82-3) is a protected, enantiomerically pure amino acid derivative widely utilized as a key building block in pharmaceutical synthesis and peptide chemistry. The compound features a tert‑butoxycarbonyl (BOC) protecting group on the amine functionality and a bromine substituent at the para position of the phenylalanine aromatic ring, making it particularly valuable in asymmetric synthesis and the development of complex active pharmaceutical ingredients (APIs).

The market is gaining steady momentum driven by the expanding demand for chiral intermediates in drug discovery, growing investment in peptide-based therapeutics, and the rising adoption of enantioselective synthesis across the pharmaceutical and biotechnology sectors. Furthermore, the compound’s utility in cross‑coupling reactions – such as Suzuki and Buchwald‑Hartwig reactions – continues to broaden its applicability in medicinal chemistry workflows. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), Bachem AG, AnaSpec, and Ark Pharm, among others.

(R)-N-BOC-4-Bromophenylalanine (CAS 79561-82-3) Market – View in Detailed Research Report

Top 10 Companies in the (R)-N-BOC-4-Bromophenylalanine Market (2026)

1️⃣ Sigma‑Aldrich (Merck KGaA)

Headquarters: Rahway, New Jersey, USA
Key Offering: High‑purity amino acid derivatives and custom synthesis services

Sigma‑Aldrich, part of Merck KGaA, is a global leader in chemical supply, providing high‑quality (R)-N‑BOC‑4‑Bromophenylalanine for pharmaceutical and biotechnology R&D. With extensive R&D capabilities and a robust distribution network, it supports rapid development of peptide therapeutics worldwide.

Sustainability Initiatives:

• Investment in green chemistry and waste reduction programs
• Use of renewable energy across manufacturing sites
• Carbon‑neutral shipping options for high‑value intermediates
• Continuous improvement of solvent‑free synthesis routes
• Collaboration with suppliers to reduce environmental impact

2️⃣ Bachem AG

Headquarters: Brüttisellen, Switzerland
Key Offering: Specialty chemical manufacturing of chiral intermediates

Bachem AG is renowned for its high‑purity chiral amino acids and API intermediates. Its integrated synthesis facilities and strict GMP compliance enable it to deliver (R)-N‑BOC‑4‑Bromophenylalanine with exceptional enantiomeric excess and purity to global pharma partners.

Sustainability Initiatives:

• Energy‑efficient production processes and circular economy practices
• Reduction of hazardous waste and halogenated solvent usage
• Implementation of renewable energy sources in production sites
• Partnerships with suppliers for sustainable raw material sourcing
• Continuous monitoring of environmental impact metrics

3️⃣ AnaSpec

Headquarters: West Chester, Pennsylvania, USA
Key Offering: Custom synthesis of specialty chemicals

AnaSpec offers tailored synthesis of protected amino acids, including (R)-N‑BOC‑4‑Bromophenylalanine, with rapid turnaround and high purity. Its flexible manufacturing platform supports diverse R&D needs across the pharmaceutical industry.

Sustainability Initiatives:

• Use of green solvents and minimized waste generation
• Carbon footprint monitoring and reduction targets
• Energy‑efficient laboratory operations
• Recycling of by‑products and solvents
• Supplier engagement for sustainable sourcing

4️⃣ Ark Pharm

Headquarters: Rockville, Maryland, USA
Key Offering: Pharmaceutical intermediates and custom manufacturing

Ark Pharm specializes in API intermediates, providing high‑purity (R)-N‑BOC‑4‑Bromophenylalanine with GMP‑certified facilities. It supports rapid scale‑up for peptide‑based therapeutics and complex drug candidates.

Sustainability Initiatives:

• Renewable energy adoption across production sites
• Waste minimization and solvent recycling programs
• Eco‑friendly packaging and logistics solutions
• Carbon‑neutral shipping options for high‑value intermediates
• Continuous improvement of environmental performance metrics

5️⃣ Biosynth AG

Headquarters: Gossau, Switzerland
Key Offering: Specialty chemical manufacturing of chiral intermediates

Biosynth AG delivers high‑purity chiral building blocks, including (R)-N‑BOC‑4‑Bromophenylalanine, with advanced synthesis capabilities and strong R&D collaboration with pharma partners.

Sustainability Initiatives:

• Energy‑efficient synthesis processes and circular initiatives
• Reduction of hazardous waste and halogenated solvent usage
• Use of renewable energy sources in production
• Partnerships for sustainable raw material sourcing
• Continuous monitoring of environmental impact

6️⃣ Iris Biotech GmbH

Headquarters: Berlin, Germany
Key Offering: Custom synthesis of protected amino acids

Iris Biotech offers tailored synthesis solutions for chiral intermediates, focusing on purity and process optimization for pharmaceutical R&D.

Sustainability Initiatives:

• Green chemistry practices and solvent reduction
• Energy‑efficient laboratory operations
• Waste minimization and recycling programs
• Supplier engagement for sustainable sourcing
• Continuous improvement of environmental metrics

7️⃣ Chem‑Impex International, Inc.

Headquarters: Brooklyn, New York, USA
Key Offering: Specialty chemicals and custom synthesis

Chem‑Impex provides high‑quality amino acids and custom synthesis services for the pharmaceutical and biotechnology sectors, supporting rapid development of peptide therapeutics.

Sustainability Initiatives:

• Sustainable sourcing of raw materials
• Reduced solvent usage and waste generation
• Energy‑efficient production processes
• Eco‑friendly packaging and logistics
• Continuous improvement of environmental performance

8️⃣ Activate Scientific, LLC

Headquarters: Boston, Massachusetts, USA
Key Offering: Custom synthesis and analytical services

Activate Scientific offers custom synthesis of chiral intermediates and comprehensive analytical support, ensuring high purity and rapid delivery for pharma R&D.

Sustainability Initiatives:

• Use of renewable energy in production facilities
• Green chemistry practices and solvent reduction
• Waste minimization and recycling programs
• Carbon footprint monitoring and reduction targets
• Supplier engagement for sustainable sourcing

9️⃣ Combi‑Blocks Inc.

Headquarters: West Chester, Pennsylvania, USA
Key Offering: Custom peptide reagents and specialty chemicals

Combi‑Blocks provides custom synthesis of protected amino acids and peptide building blocks, supporting rapid development of peptide therapeutics and research reagents.

Sustainability Initiatives:

• Eco‑friendly production processes and waste reduction
• Use of green solvents and minimized solvent waste
• Energy‑efficient laboratory operations
• Carbon‑neutral shipping options for high‑value intermediates
• Continuous improvement of environmental performance

🔟 PharmaBlock Sciences

Headquarters: Nanjing, China
Key Offering: Custom synthesis and large‑scale production

PharmaBlock Sciences offers large‑scale production of chiral intermediates with a focus on cost‑efficiency and rapid scale‑up for global pharma partners.

Sustainability Initiatives:

• Energy‑efficient manufacturing and renewable energy adoption
• Green chemistry practices and solvent reduction
• Waste minimization and recycling programs
• Carbon‑neutral logistics for high‑value intermediates
• Continuous improvement of environmental impact metrics

Download FREE Sample Report: (R)-N‑BOC‑4‑Bromophenylalanine (CAS 79561‑82‑3) Market – View in Detailed Research Report

---

Get Full Report: (R)-N‑BOC‑4‑Bromophenylalanine (CAS 79561‑82‑3) Market – View in Detailed Research Report

---

📈 Outlook: The Future of (R)-N‑BOC‑4‑Bromophenylalanine Market

The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, reflecting a robust CAGR of 6.9%. This growth is driven by increasing demand for chiral intermediates in peptide‑based therapeutics, expanding investment in custom synthesis services, and the rising adoption of enantioselective synthesis across the pharmaceutical and biotechnology sectors. Continued advancements in flow chemistry, continuous manufacturing, and green chemistry practices will further accelerate market penetration, particularly in Asia‑Pacific, where production capacity is expanding rapidly.

📊 Future Trends Shaping the Market

• Emerging applications in PROTACs and targeted protein degradation therapies.
• Expansion of cross‑coupling reactions such as Suzuki and Buchwald‑Hartwig for complex API synthesis.
• Growth of personalized medicine and bioconjugate therapies driving demand for high‑purity chiral intermediates.
• Adoption of flow chemistry and continuous manufacturing to improve yields and reduce waste.
• Increased focus on sustainability and green chemistry to meet regulatory and market expectations.